


WELCOME

to the Unique world of **Pharmacare Premium**





Pharmacare Premium Limited is a Malta-registered Company, with an EU-GMP approved site for:

- Manufacturing and Packaging of solid dosage forms (High Potency)
- Testing and Certification of Medicinal Products (Conventional, High Potency, Chemical and Microbiological)
- Investigational Medicinal Products
 (Manufacturing, importation, testing and certification)

Manufacturing/Importation License No. ML029. GMP Certificate No. MT/011HM/2013



Pharmacare Premium's current business activities include:

- Development/Co-Development and out-licensing of high-potency products
- Supply of the company's portfolio of High-Potency products in the EU, MENA and other markets
- Contract Development
- Contract manufacturing
- Contract testing and EU batch release





Pharmacare Premium's current High-Potency products:

- Registered in EU and other countries
- Available for out-licensing and supply

Product	Dosage
Anastrozole	1mg tablets
Letrozole	2.5mg tablets
Bicalutamide	50mg / 150mg tablets
Capecitabine	150mg / 500mg tablets



Pharmacare Premium's Current Product Range

- Registered in EU and other countries*
- Available for out-licensing and supply

Anastrozole	1mg tablets
Letrozole	2.5mg tablets
Bicalutamide	50mg / 150mg tablets
Capecitabine	150mg / 500mg tablets
Mycophenolate Mofetil	500mg tablets



^{*} Malta, Portugal, Latvia, Algeria, Tunisia, Egypt, Libya, Jordan, Syria, Lebanon, Iraq, Vietnam, Philippines, Belarus, Canada

Pharmacare Premium's pipeline products:

- Pharmacare has a pipeline of 5+2 products currently under development. With 2 developments having successfully passed clinical trials and two products in start development
- Additional products are being evaluated for possible development or co-development.
- Available for out-licensing and supply.

Details available on request



Pharmacare Premium's Pipeline

Generic Name	Brand Name	Molecule Patent Exp.	EU Patent Exp.	Malta Patent	Status	Dossier Ready
Sorafenib	Nexavar (Bayer)	1/2020	7/2021	No patent	Bio-Trial Pass	Q1-2020
Sunitinib	Sutent (Pfizer)	2/2021	7/2021	No patent	Bio-Trial Pass	Q1-2020
Pazopanib	Votrient (Novartis)	12/2021	6/2025	No patent	Pending	Q2-2020
Teriflunomide	Aubagio (Sanofi)	4/2022	2/2027	No patent	Pending	Q3-2020
Nilotinib	Tasigna (Novartis)	7/2023	7/2023	No patent	Pending	Q2-2021





High Potency
Manufacturing
and Packaging

- ✓ 0.5Kg 150Kg batch size
- Dry and wet granulation
- ✓ Tabletting and capsule filling
- ✓ Aqueous film-coating
- Packaging of tablets and capsules in both thermoformed and coldformed blisters
- ✓ Serialization



& EU RELEASE

- Full physical, chemical and microbial testing
- Batch certification and EU releasing by a Qualified Person
- ✓ Licensed for high-potency products
- Bulk and finished products




Pilot-Scale Production and Formulation

- ✓ Wet Granulation and FBD (0.5-5Kg)
- ✓ Cone Mill
- ✓ Single-punch tablet press
- √ 4-station tablet press
- ✓ Manual capsule filling
- ✓ Pilot-scale tablet press (9,600 tab/h)
- √ Coating (0.5-6Kg)




Management of Contract testing and Manufacturing Projects:





Management of Development Projects:





Pharmacare Premium's current customers include:

- SANDOZ (NOVARTIS) Switzerland
- SALUTAS Germany
- STADA Germany
- > AET Germany
- KERN Spain
- > KRKA Slovenia
- HELM Germany
- POLPHARMA Poland
- MEDAC Germany
- > INTAS India

- AZEVEDOS Portugal
- > VALEANT Slovakia
- CIPLA India
- > ACCORD UK
- WELDING Germany
- ► EDICTA Croatia
- BLUEFISH Portugal
- ➤ GLENMARK Czech
- EGIS Hungary
- VIPHARM Poland





- > Total land area 7,800 m²
- > Footprint of built area 4,600 m²
- > Total floor area 5,900 m²
- Production area (High Potency Solids) 1,100 m²
- ➤ Building ready for additional production line 1,300 m²
- ➤ Laboratories (chemistry and microbiology) 450 m²
- ➤ Warehouses: 800 m² (capacity of 650 pallets)

